Table 1.
Prevalence of resistance associated substitutions (RASs) and treatment outcome polymorphism (TOPs) at baseline and 12 weeks post treatment (12WPT).
| Protein | RAS/TOP | Prevalence at baseline (n) | Prevalence at 12WPT (n) | P-value | Proportion of RAS/TOP at 12WPT not present at baseline (n) |
|---|---|---|---|---|---|
| Previously characterised RAS | |||||
| NS5B | 150V | 41% (204/501) | 60% (43/72) | 8.77 × 10−4 | 9% (4/43) |
| NS5B | 159F | 0% (1/501) | 6% (4/72) | 1.47 × 10−5 | 75% (3/4) |
| TOPs | |||||
| NS2 | 119A | 4% (22/505) | 8% (6/72) | 9.37 × 10−2 | 17% (1/6) |
| NS2 | 132V | 20% (100/506) | 30% (22/72) | 1.94 × 10−2 | 0% (0/21) |
| NS3 | 67V | 44% (222/506) | 56% (41/73) | 2.33 × 10−2 | 7% (3/41) |
The percentage of the population with each RAS or TOP is shown at baseline and 12WPT. These distributions were compared using a one-sided binomial test and the P-value is shown (nominal P-value, not adjusted for multiple comparison). The percentage of patients where the amino acid at baseline has changed to the RAS or TOP in post-treatment sequence is also shown.